July 30, 2024Open Access
View Full PaperStatus and timing of angiotensin receptor–neprilysin inhibitor implementation in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry
Key Points
Key points are not available for this paper at this time.
Abstract
We explored timing, settings and predictors of angiotensin receptor-neprilysin inhibitor (ARNI) initiation in a large, nationwide cohort of patients with heart failure (HF) with reduced ejection fraction (HFrEF).